Marshall Fordyce sold $930k of VERA
PRESIDENT AND CEO at Vera Therapeutics, Inc.. 19,375 shares at an average of $47.98, traded Nov 25, 2024, filed Nov 27, 2024.
Score components
- +25RoleCEO
- +24Trade size$930k at market
- +5Share of holdings soldSold 21% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.2%, 3m -43.1%, 6m -61.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027840, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | MOption exercise Class A Common Stock10b5-1 | +6,579 | $2.90 | $19k | 92,521 | Nov 27, 2024 |
| Nov 25, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -6,579 | $47.05 | $310k | 85,942 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Class A Common Stock10b5-1 | +7,665 | $2.90 | $22k | 93,607 | Nov 27, 2024 |
| Nov 25, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -7,665 | $48.18 | $369k | 85,942 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,381 | $2.90 | $4,000 | 87,323 | Nov 27, 2024 |
| Nov 25, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,381 | $48.80 | $67k | 85,942 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,875 | $2.90 | $5,432 | 87,817 | Nov 27, 2024 |
| Nov 25, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,875 | $48.76 | $91k | 85,942 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,875 | $2.90 | $5,432 | 87,817 | Nov 27, 2024 |
| Nov 25, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,875 | $49.00 | $92k | 85,942 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,625 | $0.00 | $0 | 722,962 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 721,087 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 719,212 | Nov 27, 2024 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $680k 18,500 shares | -7% | |
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $702k 18,500 shares | -7% | |
| 20Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $2.0M 46,250 shares | -16% | |
| 35Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $2.0M 46,250 shares | -23% | |
| 26Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $702k 18,500 shares | -9% | |
| 26Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $680k 18,500 shares | -8% | |
| 30Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $1.0M 22,951 shares | -9% | |
| 39Weak | Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.